HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
MNOV
MediciNova, Inc.
There isn't enough reported data to score MNOV yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
MNOV Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Weak | |
| Unavailable |
MNOV's profitability and cash flow are currently weak. There isn't enough data to rate its revenue and balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
MNOV PE Valuation
MNOV has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
MNOV Forward outlook
There aren't enough analyst estimates for MNOV to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has the edge over MNOV on earnings, with more consistent year-over-year improvement.
MNOV Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.21 | +$0.04 |
| Q2 2026 | -$0.21 | +$0.04 |
| Q1 2026 | -$0.23 | $0.00 |
| Q4 2025 | -$0.24 | -$0.01 |
| Q3 2025 | -$0.25 | -$0.04 |
| Q2 2025 | -$0.25 | -$0.09 |
| Q1 2025 | -$0.23 | -$0.06 |
| Q4 2024 | -$0.23 | -$0.06 |
MNOV is still losing money, but less than at its worst: $0.21 per share over the past year, against $0.31 at its worst in late 2020.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over MNOV in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over MNOV on profitability, with a higher operating margin.
MNOV Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $138.6K | +12% |
| Q2 2026 | $458.4K | +241% |
MNOV's revenue is recovering but still below its 2021 peak: $138,555 last quarter, up 12% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -2209% | +533 points |
| Q2 2026 | -554% | +2126 points |
| Q1 2026 | -1517% | N/A |
| Q4 2025 | -2038% | N/A |
| Q3 2025 | -2742% | N/A |
| Q2 2025 | -2680% | N/A |
| Q3 2023 | -115% | N/A |
| Q3 2021 | -9605% | N/A |
MNOV's operating margin was −2209% last quarter, up 533 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
MNOV Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$3.5M | +$302.6K |
| Q4 2025 | -$2M | -$85.1K |
| Q1 2025 | -$3.8M | +$84.6K |
| Q4 2024 | -$1.9M | -$1.4M |
| Q3 2024 | -$2M | -$657.8K |
| Q1 2024 | -$3.9M | -$690.8K |
| Q1 2023 | -$3.2M | +$551K |
| Q4 2021 | -$3.6M | -$1.7M |
MNOV has burned cash in almost every quarter: −$10M over the past year, against −$12M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over MNOV on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
MNOV Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +157K shares |
| 1 year | +0.7% | +332K shares |
| 3 years | +0.7% | +332K shares |
| 5 years | +0.8% | +390K shares |
| Available history | +14% | +6.2M shares |
MNOV has 49M diluted shares, up 0.7% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
MNOV Net Leverage
MNOV's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
MNOV Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 46.6 | Neutral |
| Stochastic | 4.9 | Oversold |
MNOV's weekly RSI is 47 (neutral) and its Stochastic is 5 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
MNOV PE vs Healthcare Sector
MNOV has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
MNOV Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.62 | 14% below |
| 20 week MA | $1.60 | 13% below |
| 50 week MA | $1.51 | 7.3% below |
| 100 week MA | $1.50 | 6.7% below |
| 200 week MA | $1.67 | 16% below |
MNOV is in a downtrend: it's below all five of its weekly moving averages, and 16% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
MNOV Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $6.50 | $5.63 | -13% |
| 2021 | $5.63 | $2.79 | -50% |
| 2022 | $2.79 | $2.00 | -28% |
| 2023 | $2.00 | $1.50 | -25% |
| 2024 | $1.50 | $2.07 | +38% |
| 2025 | $2.07 | $1.27 | -39% |
| 2026 YTD | $1.27 | $1.40 | +10% |
MNOV has the edge over HIMS on returns for 2026, with the stronger performance.